WO1999057284A3 - Attenuated influenza viruses - Google Patents

Attenuated influenza viruses Download PDF

Info

Publication number
WO1999057284A3
WO1999057284A3 PCT/GB1999/001413 GB9901413W WO9957284A3 WO 1999057284 A3 WO1999057284 A3 WO 1999057284A3 GB 9901413 W GB9901413 W GB 9901413W WO 9957284 A3 WO9957284 A3 WO 9957284A3
Authority
WO
WIPO (PCT)
Prior art keywords
attenuated
protein
influenza virus
attenuated influenza
coding sequence
Prior art date
Application number
PCT/GB1999/001413
Other languages
French (fr)
Other versions
WO1999057284A2 (en
Inventor
George Gow Brownlee
Ervin Fodor
Peter Palese
Adolfo Garcia-Sastre
Original Assignee
Isis Innovation
George Gow Brownlee
Ervin Fodor
Peter Palese
Garcia Sastre Adolfo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, George Gow Brownlee, Ervin Fodor, Peter Palese, Garcia Sastre Adolfo filed Critical Isis Innovation
Priority to EP99919444A priority Critical patent/EP1075524A2/en
Priority to JP2000547239A priority patent/JP2002513575A/en
Priority to CA002327584A priority patent/CA2327584A1/en
Priority to AU37230/99A priority patent/AU3723099A/en
Publication of WO1999057284A2 publication Critical patent/WO1999057284A2/en
Publication of WO1999057284A3 publication Critical patent/WO1999057284A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

An attenuated influenza virus carrying a genomic nucleic acid segment which comprises 5' and 3' non-coding regions providing a mutated duplex region of an influenza virus RNA genomic segment operably-linked to a protein coding sequence for an influenza viral protein or a functional modification thereof, wherein said duplex region has at least one base-pair substitution such that expression of said protein-coding sequence in cells infected by said virus is reduced to give an attenuated phenotype. The attenuated influenza virus can be used in a vaccine.
PCT/GB1999/001413 1998-05-06 1999-05-06 Attenuated influenza viruses WO1999057284A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99919444A EP1075524A2 (en) 1998-05-06 1999-05-06 Attenuated influenza viruses
JP2000547239A JP2002513575A (en) 1998-05-06 1999-05-06 Attenuated influenza virus
CA002327584A CA2327584A1 (en) 1998-05-06 1999-05-06 Attenuated influenza viruses
AU37230/99A AU3723099A (en) 1998-05-06 1999-05-06 Attenuated influenza viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809666.2A GB9809666D0 (en) 1998-05-06 1998-05-06 Modified viruses
GB9809666.2 1998-05-06

Publications (2)

Publication Number Publication Date
WO1999057284A2 WO1999057284A2 (en) 1999-11-11
WO1999057284A3 true WO1999057284A3 (en) 1999-12-29

Family

ID=10831535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001413 WO1999057284A2 (en) 1998-05-06 1999-05-06 Attenuated influenza viruses

Country Status (6)

Country Link
EP (1) EP1075524A2 (en)
JP (1) JP2002513575A (en)
AU (1) AU3723099A (en)
CA (1) CA2327584A1 (en)
GB (1) GB9809666D0 (en)
WO (1) WO1999057284A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913892B2 (en) 2005-04-21 2018-03-13 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6830748B1 (en) 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ES2496315T3 (en) * 2005-10-19 2014-09-18 University Of Florida Research Foundation, Incorporated Materials for the control of respiratory disease in canines
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN102946900A (en) 2010-03-11 2013-02-27 免疫设计公司 Vaccines for pandemic influenza

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0704533A1 (en) * 1994-09-30 1996-04-03 Bayer Ag An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0704533A1 (en) * 1994-09-30 1996-04-03 Bayer Ag An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGMANN M AND MUSTER T: "The relative amount of influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment", JOURNAL OF GENERAL VIROLOGY, vol. 76, no. 12, December 1995 (1995-12-01), READING GB, pages 3211 - 3215, XP002112523 *
FODOR E ET AL.: "Attenuation of influenza A virus mRNA levels by promoter mutations", JOURNAL OF VIROLOGY, vol. 72, no. 8, August 1998 (1998-08-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 6283 - 6290, XP002112525 *
KIM H-J ET AL: "Mutational analysis of the RNA-fork model for the influenza A virus vRNA promoter in vivo", JOURNAL OF GENERAL VIROLOGY, vol. 78, no. 2, February 1997 (1997-02-01), READING GB, pages 353 - 357, XP002112524 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913892B2 (en) 2005-04-21 2018-03-13 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines

Also Published As

Publication number Publication date
CA2327584A1 (en) 1999-11-11
AU3723099A (en) 1999-11-23
EP1075524A2 (en) 2001-02-14
WO1999057284A2 (en) 1999-11-11
JP2002513575A (en) 2002-05-14
GB9809666D0 (en) 1998-07-01

Similar Documents

Publication Publication Date Title
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
BRPI0309631A8 (en) tetravalent dengue vaccine containing a trivial deletion of 30 nucleotides in the utr-31 'of dengue types 1,2,3 and 4, or chimeric dengue antigenic viruses 1,2,3 and 4
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
EP1394259A3 (en) Recombinant infectious non-segmented negative strand RNA virus
BR9712138A (en) Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.
HK1159188A1 (en) Recombinant newcastle disease virus rna expression systems and vaccines rna
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
YU37502A (en) Infectious clones
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
MXPA03000061A (en) Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof.
WO1999057284A3 (en) Attenuated influenza viruses
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
WO2002008436A3 (en) Mini-adenoviral vector system for vaccination
WO1998024912A3 (en) Recombinant plague vaccine
WO1993025707A3 (en) Methods for amplification of genome and mixtures of initiator oligonucleotides for the detection and identification of related genomic sequences
HUP9904201A1 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
MD2149G2 (en) Oligonucleotide primer for hepatitis C virus RNA detection
EP0997529A3 (en) Feline immunodeficiency virus strain FIV-141 and uses thereof
WO2002061048A3 (en) In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses
AU3955400A (en) The full gene sequence of the donkey leukocyte vaccine strain of the equine infectious anemia virus and their application
PT1254663E (en) ANTIVIRAL AGENT
WO2000053775A3 (en) Prevention and treatment of viral infections
TH11327EX (en) Genomic C, DNA and Polypeptide Antigens of Non-A, Non-B Hepatitis Viruses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2327584

Country of ref document: CA

Ref country code: CA

Ref document number: 2327584

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 37230/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999919444

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999919444

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09674892

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999919444

Country of ref document: EP